Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden and the Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. Newbury Pharmaceuticals AB (publ) was incorporated in 2020 and is based in Lund, Sweden.
Frequently asked questions
What sector does Newbury Pharmaceuticals AB (NEWBRY) operate in?
Newbury Pharmaceuticals AB belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Newbury Pharmaceuticals AB (NEWBRY) current stock price?
As of the latest data, Newbury Pharmaceuticals AB stock price is SEK 2.88, with a previous close of SEK 2.72. Newbury Pharmaceuticals AB gained SEK 0.16 in the last trading session, representing a 5.88% increase.
What is Newbury Pharmaceuticals AB (NEWBRY) current market capitalization?
Newbury Pharmaceuticals AB market cap is approximately 87.55 million.
What is Newbury Pharmaceuticals AB (NEWBRY) Earnings Per Share (EPS)?
The trailing EPS is -SEK 0.88, and the forward EPS is SEK 0.60.
What is Newbury Pharmaceuticals AB (NEWBRY) EBITDA?
Newbury Pharmaceuticals AB EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -3.68 million.
Does Newbury Pharmaceuticals AB (NEWBRY) pay dividends?
No. Newbury Pharmaceuticals AB does not pay a dividend.
What is Newbury Pharmaceuticals AB (NEWBRY) beta (volatility) score?
Newbury Pharmaceuticals AB has a beta of 1.264, suggesting it is more volatile than the market.